Wall Street analysts expect that PDL BioPharma Inc (NASDAQ:PDLI) will report $0.03 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for PDL BioPharma’s earnings. PDL BioPharma reported earnings of $0.01 per share in the same quarter last year, which would indicate a positive year over year growth rate of 200%. The firm is scheduled to issue its next earnings results after the market closes on Thursday, March 8th.

On average, analysts expect that PDL BioPharma will report full-year earnings of $0.60 per share for the current fiscal year. For the next fiscal year, analysts expect that the business will report earnings of $0.10 per share. Zacks’ EPS averages are an average based on a survey of analysts that follow PDL BioPharma.

A number of analysts have recently weighed in on the company. BidaskClub cut PDL BioPharma from a “sell” rating to a “strong sell” rating in a research report on Tuesday, February 13th. ValuEngine raised PDL BioPharma from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. Cowen reissued a “hold” rating and issued a $3.00 price objective on shares of PDL BioPharma in a research report on Friday, October 27th. Finally, Zacks Investment Research cut PDL BioPharma from a “buy” rating to a “hold” rating in a research report on Monday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $3.33.

Shares of PDL BioPharma (PDLI) traded down $0.02 during midday trading on Thursday, reaching $2.45. The company’s stock had a trading volume of 1,423,895 shares, compared to its average volume of 1,240,000. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.16 and a quick ratio of 3.10. The company has a market cap of $378.13, a PE ratio of 4.90 and a beta of 0.48. PDL BioPharma has a 1-year low of $1.96 and a 1-year high of $3.55.

Several institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors boosted its position in shares of PDL BioPharma by 4.7% in the 2nd quarter. Nationwide Fund Advisors now owns 109,961 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 4,900 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of PDL BioPharma by 18.4% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 65,612 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 10,189 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of PDL BioPharma by 15.7% in the 2nd quarter. Voya Investment Management LLC now owns 82,612 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 11,235 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of PDL BioPharma by 7.0% in the 2nd quarter. Alliancebernstein L.P. now owns 275,422 shares of the biotechnology company’s stock worth $680,000 after purchasing an additional 18,100 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in PDL BioPharma by 64.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 49,062 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 19,144 shares during the last quarter. 90.52% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/02/20/613098.html.

About PDL BioPharma

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Get a free copy of the Zacks research report on PDL BioPharma (PDLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply